DESCRIPTION
MECHANISM OF ACTION
Zoledronic acid is a potent inhibitor of bone resorption. It inhibits osteoclast proliferation (Coxon et al 2000) and induces osteoclast
apoptotic cell death (Benford et al 2001).
ABSORPTION
Zoledronic acid concentration in plasma after the infusion decreases rapidly due to the increased absorption of the drug by the bone. However,
small amounts of zoledronic acid can be detected in plasma several days after the infusion, representing the drug released gradually
from the bone during bone turn-over.
DISTRIBUTION
In vivo distribution of zoledronic acid in a bisphosphonate-metal complex-based nanoparticle formulation synthesized by a reverse microemulsion method.
INDICATIONS
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men
and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women.14,15,16 Zoledronic acid is
also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis
DOSAGE RANGE
1. Patients with multiple myeloma and patients with documented bone metastases from solid
tumors, in conjunction with standard antineoplastic therapy.
2. Patients with multiple myeloma and patients with documented bone metastases from
solid tumors, in conjunction with standard antineoplastic therapy.
3. Treatment of hypercalcemia of malignancy (albumin-corrected calcium equal 12 mg/dL or grater).
4. Paget's disease of bone with elevations in serum alkaline phosphatase of two times or higher than upper
limit of age- specific normal reference range.
DRUG INTERACTIONS
While using this medication, you should not be treated with other bisphosphonates, including other brands of zoledronic acid used
to prevent or treat bone loss (osteoporosis). Some products that may interact with this drug include: calcium-containing IV
fluids, "water pills" (diuretics such as bumetanide, furosemide).
SPECIAL CONSIDERATIONS
Zoledronic acid should not be used during pregnancy. Women of childbearing age should be advised to avoid becoming pregnant
while on zoledronic acid, as it may cause fetal harm when administered to pregnant women. Severe bone, joint, and muscle pain
may occur while on zoledronic acid.
TOXICITY
Administration of Zoledronic Acid Injection 4 mg given as a 5-minute intravenous infusion has been shown to result in an increased risk of renal
toxicity, as measured by increases in serum creatinine, which can progress to renal failure.
SPECIFICATION
Login To Comment